Sunrun Inc vs Revvity Inc — how do they compare? Sunrun Inc trades at $7.53 (market cap $1.83B), while Revvity Inc trades at $154.75 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 9.3× Sunrun Inc's market cap, and Revvity Inc pays a 0.18% dividend while Sunrun Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sunrun Inc for 16 Days and Revvity Inc for 12 Days on average.
| RUN | RVTY | |
|---|---|---|
Market Cap | $1.83B | $16.98B |
Volume | 8,672,852 | 1,456,900 |
Sector | Energy | Health |
52-Week High | $21.41 | $157.36 |
52-Week Low | $7.59 | $82.26 |
Typical Hold Time | 16 Days | 12 Days |
Enterprise Value | $16.35B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Sunrun (RUN) trades at $7.58, down 0.39% on the day, reflecting a bearish technical trend. The stock shows attractive valuation ratios with a P/E of 5.16 and P/S of 0.59, while recent quarterly earnings have consistently beaten expectations. However, cash flow from operations remains negative, and the company faces headwinds from high borrowing costs impacting the solar sector. Positive developments include a record 580 MW grid dispatch with Tesla and expanded partnerships for distributed computing.
The outlook is mixed: strong analyst support with a $16.33 price target suggests significant upside, but operational cash burn and sector volatility pose risks. Investors should weigh low valuations against execution challenges and macroeconomic pressures affecting solar financing.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →